Swiss genomic analytics and AI firm Sophia Genetics has closed on a $30 million Series D round, led by new investor Balderton Capital.
A number of genomics companies have made Technology Review's list of smart companies.
Swiss informatics firm Sophia Genetics has moved into liquid biopsies with an update to its SOPHiA AI system, changing how clinicians treat some cancers.
Hospitals in Morocco, Cameroon, and South Africa recently adopted its SOPHiA artificial intelligence offering, the firm's first crop of African customers.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.
The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.
The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.
Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.
Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.